Progression of extrapyramidal signs in Alzheimer's disease: Clinical and neuropathological correlates

Journal of Alzheimer's Disease

Volumn 49, Issue 4, 2015, Pages 1085-1093

  Tosto, Giuseppe ^a,b   Monsell, Sarah E ^d   Hawes, Stephen E ^d   Bruno, Giuseppe ^e   Mayeux, Richard ^a,b,c  

^a NewYork Presbyterian Hospital   (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; extrapyramidal signs; K means clustering; Lewy bodies; longitudinal studies

Indexed keywords

AGED; ALZHEIMER DISEASE; APATHY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COGNITIVE DEFECT; DELUSION; DEMENTIA; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; HALLUCINATION; HIPPOCAMPAL SCLEROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE; ALGORITHM; CLUSTER ANALYSIS; FACTUAL DATABASE; LONGITUDINAL STUDY; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; ALGORITHMS; ALZHEIMER DISEASE; CLUSTER ANALYSIS; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84953729120     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150244     Document Type: Article

References (27)

1. Alzheimer's Association. (2013). 2013 Alzheimer's disease facts, and figures. Alzheimers Dement. 9, 208-245.
2. Portet F, Scarmeas N, Cosentino S, Helzner EP, SternY(2009) Extrapyramidal signs before, and after diagnosis of incident Alzheimer disease in a prospective population study. Arch Neurol. 66, 1120-1126.
3. Mangone C. (2003). [Clinical heterogeneity of Alzheimer's disease. Different clinical profiles can predict the progression rate]. Rev Neurol. 38, 675-681.
4. Paulsen JS, Salmon D, Thal L, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter C, Thomas R, Grant I, JesteD(2000) Incidence of, and risk factors for hallucinations, and delusions in patients with probable AD. Neurology. 54, 1965-1971.
5. Ropacki SA, Jeste DV. (2005). Epidemiology of, and risk factors for psychosis of Alzheimer's disease: A review of 55 studies published from 1990 to 2003. Am J Psychiatry. 162, 2022-2030.
6. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M; Consortium on DLB. (2005). Diagnosis, and management of dementia with Lewy bodies Third report of the DLB consortium. Neurology. 65, 1863-1872.
7. Zhu K, Hilten JJ, Putter H, Marinus J. (2013). Risk factors for hallucinations in Parkinson's disease: Results from a large prospective cohort study. Mov Disord. 28, 755-762.
8. Halliday GM, Leverenz JB, Schneider JS, Adler CH. (2014). The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 29, 634-650.
9. Swerdlow RH, Newell KL. (2012). "Untangling" the relationship between Alzheimer disease, and dementia with Lewy bodies. Neurology. 6, 1938-1939.
10. Genolini C, Falissard B. (2011). KmL: A package to cluster longitudinal data. Comput Methods Programs Biomed. 104, e112-e121.
11. Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA, NIA Alzheimer's Disease Centers. (2007). The National Alzheimer's Coordinating Center (NACC) database: The uniform data set. Alzheimer Dis Assoc Disord. 21, 249-258.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. (1984). Clinical diagnosis of Alzheimer's disease Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health, and Human Services Task Force on Alzheimer's Disease. Neurology. 34, 939-939.
13. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N; Movement Disorder Society UPDRS Revision Task Force. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation, and clinimetric testing results. Mov Disord. 23, 2129-2170.
14. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST. (2000). Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 12, 233-239.
15. Folstein MF, Folstein SE, McHugh PR. (1975). "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12, 189-198.
16. Morris JC. (1993). The Clinical Dementia Rating (CDR): Current version, and scoring rules. Neurology. 43, 2412-2414.
17. Mirra S, Hart MN, Terry R. (1993). Making the diagnosis of Alzheimer's disease A primer for practicing pathologists. Arch Pathol Lab Med. 117, 132-144.
18. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. (2006). Staging of Alzheimer disease-Associated neurofibrillary pathology using paraffin sections, and immunocytochemistry. Acta Neuropathol. 112, 389-404.
19. Calinski T, Harabasz J. (1974) A dendrite method for cluster analysis. Commun Stat Theory Methods. 3, 1-27.
20. Zeger SL, Liang K-Y. (1992). An overview of methods for the analysis of longitudinal data. Stat Med. 11, 1825-1839.
21. Richards M, Marder K, Bell K, Dooneief G, Mayeux R, Stern Y. (1991). Interrater reliability of extrapyramidal signs in a group assessed for dementia. Arch Neurol. 48, 1147-1149.
22. Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, Householder E, Ayutyanont N, Roontiva A, Bauer RJ, Eisen P, Shaw LM, Davatzikos C, Weiner MW, Reiman EM, Morris JC, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative (ADNI). (2013). Clinical, and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun. 1, 65.
23. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay M, Hofstetter R, Klauber M, et al. (1990). The Lewy body variant of Alzheimer's disease A clinical, and pathologic entity. Neurology. 40, 1-8.
24. Stern Y, Jacobs D, Goldman J, Gomez-Tortosa E, Hyman BT, Liu Y, Troncoso J, Marder K, Tang MX, Brandt J, Albert M. (2001). An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. Arch Neurol. 58, 460-465.
25. Liu Y, Stern Y, Chun MR, Jacobs DM, Yau P, Goldman JE. (1997). Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol. 41, 368-374.
26. Schneider JA, Li J-L, Li Y, Wilson RS, Kordower JH, Bennett DA. (2006). Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol. 59, 166-173.
27. Pham DT, Dimov SS, Nguyen C. (2005). Selection of K in Kmeans clustering. Proc IME C J Mech Eng Sci. 219, 103-119.